PerpEquities

Novartis AG (NVS) balance sheet

NYSE · Healthcare · Drug Manufacturers - General · 75,267 employees · CEO Vasant Narasimhan

Price
$160.79 -0.19%
Market cap
$304B
Enterprise value
$346B
Last report
Q3 '26 filed 2026-10-27
Next report
2027-02-03

At the end of Q3 '26 Novartis AG (NVS) held $8.98B in cash and short-term investments against $48.3B of debt incl. leases. Total assets $117B, total liabilities $79.6B, shareholders' equity $37.2B.

Balance sheet

Balance sheetTrendQ4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Assets
Cash & equivalents$13.4B$9.47B$7.9B$13.6B$11.5B$7.07B$6.66B$9.56B$11.4B$6.88B$7.62B$8.87B
Short-term investments$1.03B$225M$532M$411M$1.89B$130M$344M$197M$155M$100M$74M$105M
Receivables$8.12B$8.25B$8.48B$8.15B$8.21B$8.73B$9.18B$8.98B$10.9B$9.6B$9.85B$9.96B
Inventory$5.91B$5.74B$5.75B$5.94B$5.72B$5.83B$6.31B$6.42B$6.27B$6.29B$6.22B$6.1B
Other current assets$1.25B$2.76B$3.03B$3.16B$1.43B$3.36B$3.46B$3.04B$571M$3.74B$3.59B$3.71B
Current assets$30.5B$26.4B$25.7B$31.3B$29.7B$25.1B$25.9B$28.2B$30.5B$26.6B$27.4B$28.7B
Property, plant & equipment (net)$10.9B$10.5B$10.6B$11.2B$10.9B$11.1B$11.8B$12B$12.4B$12.2B$12.3B$12.3B
Long-term investments$2.7B$2.58B$2.13B$2.19B$1.13B$2.1B$2.16B$2.15B$2.3B$2.43B$2.37B$2.1B
Goodwill$23.3B$23.1B$25.2B$24.9B$24.8B$25B$25.6B$25.6B$25.6B$26.8B$26.8B$27.2B
Intangible assets$26.9B$26.3B$27.8B$27.9B$26.9B$27.5B$29.2B$29B$29.4B$40.2B$42.1B$39.8B
Deferred tax assets$8.19B$4.22B$4.4B$4.65B$4.36B$5.1B$5.2B$5.58B$5.44B$5.25B$5.28B$5.35B
Other non-current assets$1.31B$1.21B$1.66B$1.39B$4.51B$4.11B$4.47B$4.78B$10B$4.98B$5.93B$1.69B
Non-current assets$73.3B$67.9B$71.8B$72.3B$72.5B$74.8B$78.5B$79.1B$85.1B$91.9B$94.7B$88.4B
Total assets$104B$94.3B$97.5B$104B$102B$99.9B$104B$107B$116B$119B$122B$117B
Liabilities
Accounts payable$4.93B$4.06B$4.15B$4.09B$4.57B$4.26B$4.51B$4.56B$4.46B$4.32B$4.26B$4.24B
Accrued expenses$2.33B$0$0$0$2.18B$0$0$0$2.48B$0$0$0
Short-term debt$6.31B$8.34B$7.53B$6.57B$8.09B$7.8B$8.31B$7.52B$5.52B$7.62B$9.86B$9.65B
Taxes payable$1.89B$1.65B$1.92B$2.17B$2.23B$2.57B$2.83B$3.34B$2.58B$1.81B$0$2.65B
Deferred revenue$98M$0$0$0$127M$0$0$0$0$0$0$0
Other current liabilities$10.8B$15B$13.8B$15.1B$10.4B$16.7B$15.8B$16.3B$12B$17.4B$15.3B$15.7B
Current liabilities$26.4B$29.3B$27.6B$28.1B$28.7B$31.6B$31.7B$32B$27.3B$31.4B$31.7B$32.5B
Long-term debt$18.4B$17.2B$19.7B$23.8B$21.4B$21.7B$22.5B$22.6B$29.6B$37.4B$37.5B$36.7B
Lease obligations (non-current)$1.6B$1.53B$1.56B$1.6B$1.57B$1.56B$1.59B$1.64B$1.66B$1.66B$1.66B$1.68B
Deferred tax liabilities$6.13B$2.31B$2.46B$2.22B$2.42B$2.55B$2.32B$2.17B$8.02B$5.1B$5.29B$4.4B
Other non-current liabilities$4.52B$4.26B$4.31B$4.39B$4.08B$4.1B$4.24B$4.13B$2.48B$4.02B$3.9B$4.28B
Non-current liabilities$30.7B$25.3B$28B$32B$29.4B$29.9B$30.6B$30.5B$41.7B$48.2B$48.3B$47.1B
Total liabilities$57.1B$54.6B$55.6B$60.1B$58.1B$61.5B$62.3B$62.5B$69B$79.6B$80.1B$79.6B
Equity
Common stock & paid-in capital$825M$793M$793M$793M$793M$766M$766M$766M$766M$736M$736M$736M
Retained earnings$49.6B$43.8B$45.8B$46.3B$46.6B$39.8B$41.5B$43.5B$44.7B$37.3B$39.6B$39.2B
Accumulated other comprehensive income-$3.77B-$4.94B-$4.87B-$3.73B$43.3B-$2.22B-$275M$98M$694M$571M$1.21B-$2.69B
Shareholders' equity$46.7B$39.7B$41.7B$43.3B$44B$38.4B$42B$44.3B$46.1B$38.5B$41.5B$37.2B
Debt
Total debt (incl. leases)$26.3B$27.3B$29B$32.2B$31.3B$31.3B$32.6B$32B$37.1B$47B$49B$48.3B
Net debt (debt - cash)$13B$17.8B$21.1B$18.6B$19.8B$24.2B$26B$22.5B$25.7B$40.1B$41.4B$39.4B

Standardised by Financial Modeling Prep from the company's filings; outflows and costs keep the sign the provider reports. Hover a period for its end date. Amounts in USD.

Cash, investments and debt

quarter ends

The other statements

Sources

Statements, segment revenue, metrics and estimates: Financial Modeling Prep.

Data as of 2026-11-01